Janssen Healthcare Innovation
Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis
Approximately 125 million people globally are living with some form of psoriasis
Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer
An estimated 84,870 people will be diagnosed with bladder cancer in the US this year
Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults
More than 2.5 million people in Europe are living with the inflammatory bowel disease
J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients
Approximately 25% of cases are diagnosed during childhood or adolescence
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Inflammatory bowel disease is estimated to affect nearly two million people across Europe
J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer
The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC
Johnson & Johnson to invest more than $55bn in US over next four years
The commitment marks a 25% increase to the company's US investments in the past four years
Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease
An estimated three million people in the US are affected by inflammatory bowel disease
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme
More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease
J&J’s Lazcluze/Rybrevant combination granted MHRA approval for lung cancer
Approximately 47,000 people are diagnosed with lung cancer every year in the UK
J&J receives three CHMP recommendations for immunology and oncology indications
Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively
J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer
The formulation significantly reduces administration time compared to the approved intravenous version